Evidence map›Paper›PMID 35073850›Full record

ArticleBMC cancer2022

Correction to: Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.

Salonee Shah, Kerri Beckmann, Mieke Van Hemelrijck, Ben Challacombe, Rick Popert, Prokar Dasgupta, Jonah Rusere, Grace Zisengwe, Oussama Elhage, Aida Santaolalla

Abstract readPublished Erratum
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Salonee Shah *King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, UK.
Kerri Beckmann *King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, UK.
Mieke Van HemelrijckKing's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, UK.
Ben ChallacombeKing's College London & Guy's and St Thomas' NHS Foundation Trust, London, UK.
Rick PopertKing's College London & Guy's and St Thomas' NHS Foundation Trust, London, UK.
Prokar DasguptaKing's College London & Guy's and St Thomas' NHS Foundation Trust, London, UK.
Jonah RusereKing's College London & Guy's and St Thomas' NHS Foundation Trust, London, UK.
Grace ZisengweKing's College London & Guy's and St Thomas' NHS Foundation Trust, London, UK.
Oussama Elhage *King's College London & Guy's and St Thomas' NHS Foundation Trust, London, UK.
Aida Santaolalla *King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, UK. aida.santaolalla@kcl.ac.uk.

Funding

Medical Research Council MR/R014043/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35073850
PMCPMC8785474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.